News

Arise Innovation Hubs, part of Anglia Ruskin University (ARU), has launched a new grant programme. Arise ABOVE (Arise Beyond Open Innovation for Value and Entrepreneurship) will deliver innovation grants, expert support and events to unlock HealthTech and MedTech investment in Essex.

OXFORD, UK – 22 November 2023 – PrecisionLife®, a leading computational biology company focused on precision medicine in complex chronic diseases, announces the appointment of Dr Gerald Dunstan as SVP Corporate Development and Hannah Bibby as Product Strategy Lead to drive the company’s expansion into precision diagnostics and personalized healthcare.

Following a period of sustained growth, life science logistics company Biocair has relocated and expanded its Chicago office and warehouse facility. As part of its wider global growth strategy, the leading specialist has increased its 2,904 sq. ft. space by more than double, securing a new 7,213 sq. ft. facility just three miles from the key cargo complex at O’Hare International Airport.

 
New 60,000 sq ft multi-occupancy building will provide additional space for life science companies within Cambridge cluster

Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)


AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN).

Excellent to see Charles River, a Partner of One Nucleus, making progress (5 years ahead of schedule!) towards helping achieve 100%  renewable electricity globally. Read more to find out how...


Arecor Therapeutics plc

(“Arecor” or the “Group”)


FIRST PRODUCT INCORPORATING ARECOR’S ARESTAT TECHNOLOGY, AT220, LAUNCHED IN EUROPE

First commercial sale triggers milestone payment and future royalties to Arecor

Bristol Myers Squibb's (BMS) Augtyro (repotrectinib) has been approved by the US Food and Drug Administration (FDA) to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).


Lung cancer is the leading cause of cancer deaths in the US, with NSCLC representing up to 85% of all lung cancer diagnoses.


More common in individuals with little to no smoking history, the ROS1 gene alteration occurs in only up to 2% of NSCLC patients and is associated with aggressive lung cancer that can often spread to the brain.

The University of Glasgow and Kadans Science Partner, supported by Scottish Enterprise, are delighted to announce the construction of a new Health Innovation Hub in Govan, setting the stage for a thriving life sciences cluster in the area.


Work on the new Health Innovation Hub has begun, and is due for completion in summer 2025. Morrison Construction have been appointed as the main contractor. The Hub will attract new innovative businesses into the area, and deliver local benefits to the community through job creation.

Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with participation from Sanofi Ventures and the University of Cambridge Venture Fund


Unique transgenic mouse platform harnesses natural power of T cells to build a portfolio of first-in-class cancer medicines

Pages